Gilead Sciences, Inc.

GILDleader

Gilead Sciences is a research-based biopharmaceutical company that revolutionized the treatment of HIV and hepatitis C. Biktarvy has become the most prescribed HIV treatment globally, and the company is expanding aggressively into oncology through its Kite cell therapy division and antibody-drug conjugate platform.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($28.1B)

静态数据（加载实时财务…）

HIV (Biktarvy, Descovy) (55%)

Oncology (Trodelvy, Yescarta) (18%)

Liver Disease (HCV/HBV) (10%)

Veklury & Other (17%)

业务板块构成与主要客户

产品详情

Biktarvy45%

Leading single-tablet HIV regimen combining three antivirals

Veklury (Remdesivir)10%

Antiviral treatment for COVID-19 and emerging viral threats

Trodelvy/Cell Therapy25%

Oncology portfolio including ADCs and CAR-T via Kite Pharma

供应链关系

竞争对手

Pfizer Inc.

Antiviral therapies

影响: Competing in antivirals

AbbVie Inc.

Oncology pipeline overlap

影响: Competing in oncology

合作伙伴

Moderna, Inc.

Potential mRNA-based HIV vaccine collaboration

影响: Research partnership

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 Gilead Sciences, Inc. 的 AI 供应链分析。

企业信息

总部

Foster City, California, USA

成立时间

1987

员工人数

18,000+

官网

gilead.com

行业概况 — 제약 / 바이오

行业新闻